Clinical trials: Partial Seizures With or Without Secondary Generalization
Epilepsy
A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
Patients with medically refractory epilepsy will be treated by intracerebroventricular (ICV) delivery of valproate using an implantable drug pump system.
- Trial name
- NCT02899611
- Testing
- Valproate
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Cerebral Therapeutics LLC
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00698581
- Testing
- Brivaracetam
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 88 people
- Sponsor
- UCB Pharma
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
The purpose of the study is to evaluate the safety and tolerability of intravenous (iv) brivaracetam (BRV) as adjunctive therapy administered as a replacement for oral BRV at doses ranging from BRV 50 mg/day to 200 mg/day in…
- Trial name
- NCT03685630
- Testing
- Brivaracetam
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- UCB Biopharma S.P.R.L.
Focal Epilepsy
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
This is a non-randomized open-label extension study for subjects having completed protocol DA071976 or CLN100P.01.
- Trial name
- NCT04529954
- Testing
- Valproic Acid delivered to ICV
- Where
- 8 sites in Australia, Israel
- Volunteers
- 20 people
- Sponsor
- Cerebral Therapeutics LLC
Focal Epilepsy With and Without Secondary Generalization
Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment…
- Trial name
- VICTOS (NCT01673282)
- Testing
- Lacosamide
- Where
- 42 sites in Austria, Germany
- Volunteers
- 315 people
- Sponsor
- UCB Pharma GmbH
Epilepsy
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).
- Trial name
- NCT02726074
- Testing
- Perampanel
- Where
- 6 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Eisai Korea Inc.
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.